Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
Abstract. Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy. Since the Food and Drug Administration approved two CD19-CAR-T produc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2023-10-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002549 |
| _version_ | 1797646868754202624 |
|---|---|
| author | Zhihuan Yang Ying Wang Peifang Wei |
| author_facet | Zhihuan Yang Ying Wang Peifang Wei |
| author_sort | Zhihuan Yang |
| collection | DOAJ |
| description | Abstract. Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy. Since the Food and Drug Administration approved two CD19-CAR-T products for clinical treatment of relapsed/refractory acute lymphoblastic leukemia and diffuse large B cell lymphoma in 2017, five more CAR-T cell products were subsequently approved for treating multiple myeloma or B cell malignancies. Moreover, clinical trials of CAR-T cell therapy for treating other hematological malignancies are ongoing. Both China and the United States have contributed significantly to the development of clinical trials. However, CAR-T cell therapy has many limitations such as a high relapse rate, adverse side effects, and restricted availability. Various methods are being implemented in clinical trials to address these issues, some of which have demonstrated promising breakthroughs. This review summarizes developments in CAR-T cell trials and advances in CAR-T cell therapy. |
| first_indexed | 2024-03-11T15:09:00Z |
| format | Article |
| id | doaj.art-9554051eac3a4f69b4aaf0ce8de0d74e |
| institution | Directory Open Access Journal |
| issn | 0366-6999 2542-5641 |
| language | English |
| last_indexed | 2024-03-11T15:09:00Z |
| publishDate | 2023-10-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj.art-9554051eac3a4f69b4aaf0ce8de0d74e2023-10-30T03:37:50ZengWolters KluwerChinese Medical Journal0366-69992542-56412023-10-01136192285229610.1097/CM9.0000000000002549202310050-00002Clinical development of chimeric antigen receptor-T cell therapy for hematological malignanciesZhihuan Yang0Ying Wang1Peifang Wei2State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Tianjin Key Laboratory of Cell Therapy for Blood Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Tianjin Key Laboratory of Cell Therapy for Blood Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Tianjin Key Laboratory of Cell Therapy for Blood Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.Abstract. Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy. Since the Food and Drug Administration approved two CD19-CAR-T products for clinical treatment of relapsed/refractory acute lymphoblastic leukemia and diffuse large B cell lymphoma in 2017, five more CAR-T cell products were subsequently approved for treating multiple myeloma or B cell malignancies. Moreover, clinical trials of CAR-T cell therapy for treating other hematological malignancies are ongoing. Both China and the United States have contributed significantly to the development of clinical trials. However, CAR-T cell therapy has many limitations such as a high relapse rate, adverse side effects, and restricted availability. Various methods are being implemented in clinical trials to address these issues, some of which have demonstrated promising breakthroughs. This review summarizes developments in CAR-T cell trials and advances in CAR-T cell therapy.http://journals.lww.com/10.1097/CM9.0000000000002549 |
| spellingShingle | Zhihuan Yang Ying Wang Peifang Wei Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies Chinese Medical Journal |
| title | Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies |
| title_full | Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies |
| title_fullStr | Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies |
| title_full_unstemmed | Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies |
| title_short | Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies |
| title_sort | clinical development of chimeric antigen receptor t cell therapy for hematological malignancies |
| url | http://journals.lww.com/10.1097/CM9.0000000000002549 |
| work_keys_str_mv | AT zhihuanyang clinicaldevelopmentofchimericantigenreceptortcelltherapyforhematologicalmalignancies AT yingwang clinicaldevelopmentofchimericantigenreceptortcelltherapyforhematologicalmalignancies AT peifangwei clinicaldevelopmentofchimericantigenreceptortcelltherapyforhematologicalmalignancies |